; ;
The clinical trials listed in this section are open to patient recruitment. For each trial, an overview of the study design is provided together with a brief explanation of the trial objectives. A more detailed overview is available in the Members Area.
A Phase II, open-label, multicentre, dose escalation trial of imatinib followed by nilotinib in patients who have newly diagnosed, inoperable, gastrointestinal stromal tumour.
This is a Phase II, open label, multicentre study evaluating imantinib dose escalation followed by nilotinib after progressive disease, according to stratification into exon 11 and non-exon 11/WT mutational status. The functional response to therapy, as determined by FDG-PET, will be correlated with pharmacokinetics after administration.
Principal Investigators
Dr. Jayesh Desai
Royal Melbourne Hospital, Vic
An advanced oesophago-gastric cancer with weekly docetaxel, cisplatin, fluoropyrimidine (w/TCF) plus or minus panitumumab in advanced oesophago-gastric cancer.
The ATTAX3 study is a randomised, phase II study comprising two separate components. Patients with advanced oesophago-gastric cancer will be randomised to receive chemotherapy only (wTCF/X) or chemotherapy plus panitumumab. The study will evaluate the objective tumour response rate of these treatment regimes.
Principal InvestigatorA randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.
The primary study objective is to investigate whether preoperative chemoradiotherapy leads to improved survival in comparison with preoperative chemotherapy in patients undergoing adequate surgery (D1 dissection) for resectable gastric cancer.
Principal Investigators
A/Prof Trevor Leong, Radiation Oncologist, Peter MacCallum Cancer Centre
A randomised multicentre phase III study in patients with locally advanced adenocarcinoma of the pancreas; gemcitabine with or without chemoradiotherapy and with or without erlotinib.
For patients with pancreatic cancer, surgery to remove the entire tumor is the only potentially curative treatment. However, many patients have tumors that are localized but cannot be removed by surgery because the tumor is near a large blood vessel or joined to the stomach or bowel. These patients are generally treated with chemotherapy. Even with chemotherapy, their prognosis is very poor. It is not clear to doctors and researchers whether additional treatment with radiotherapy is beneficial. It is also unknown whether the newer targeted (antibody) type treatments are useful.
LAP07 is an international trial led by Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) a French collaborative research group. It will test whether a combination of chemotherapy and radiotherapy is better than chemotherapy alone in patients with localized but inoperable pancreatic cancer. It will also investigate the possible role of the newer antibody type drugs. Investigators will assess whether survival is improved with the addition of radiotherapy and the newer drugs.
Principal InvestigatorsShort Course Oncology Therapy - A Study of Adjuvant Chemotherapy in Colorectal Cancer.
An international, open-label randomised, two-arm phase III non-inferiority trial investigating a shortened duration of treatment for patients with high-risk stage II/III colorectal cancer.
The SCOT study aims to definitively answer the question of whether 12 weeks of adjuvant chemotherapy using a 5FU/oxaliplatin regimen is as effective as 24 weeks of the identical treatment in reducing cancer recurrence. In addition, if SCOT can establish equivalent efficacy with a shortened duration of adjuvant treatment, it will significantly decrease the financial burden of adjuvant treatment on a population basis, and produce vast benefits in terms of short and long term morbidity.
Principal InvestigatorsA phase III prospective randomised trial comparing laparoscopic-assisted resection versus open resection for rectal cancer.
The A La CaRT study is a rsndomised phase III trial designed to determine if laparoscopic-assisted resection is a safe, effective and feasible approach for patients with resectable rectal
cancer.
Principal Investigator
Dr Andrew Stevenson, Royal Brisbane Hospital
Supported by
Colorectal Surgical Society of Australia and New Zealand, NHMRC Clinical Trials Centre and Australasian Gastro-Intestinal Trials Group
A randomised phase II study evaluating potential biomarkers in the treatment of metastatic pancreatic cancer.
A trial to prospectively evaluate hENT1 as a predictive marker of benefit from gemcitabine treatment in metastatic pancreatic cancer.
Principal Investigator
Dr Yu Jo Chua, Medical Oncologist, Canberra Hospital
Supported by
Received funding from the Avner Nahmani pancreatic cancer research fund.
A Trial in the timing of Surgery and Adjuvant Chemotherapy for Hepatic Metastases from Colorectal Cancer
The ATTACHE trial aims to determine the differences in peri-operative morbidity between 2 groups of patients where chemotherapy is given prior to and post surgical resection versus chemotherapy given post surgical resection. This study will also assess the tolerability of chemotherapy in these two groups, compare surgical mortality between groups and determine treatment related toxicity, the response rate (RR) to pre-operative chemotherapy, the progression-free survival (PFS) for each treatment arm, the overall survival (OS) for each treatment arm and to determine the effects of treatment on the quality of life (QoL).
Principal Investigator
Conjoint Professor David Goldstein, Medical Oncologist, Prince of Wales Hospital, NSW